On July 16th, Huapont Life Sciences (002004.SZ) stated on the investor interaction platform that Hanjiang Pharmaceutical is a wholly-owned subsidiary of the company, mainly engaged in the R&D, production and sales of pharmaceutical APIs and intermediates, covering products such as steroid hormones, anthelmintics, respiratory and digestive system drugs, and has established long-term cooperation with internationally renowned pharmaceutical companies such as Abbott Laboratories, Johnson & Johnson, Eli Lilly and Co., and Merck. The specific timetable for Hanjiang Pharmaceutical's listing has not yet been determined, but Hanjiang Pharmaceutical has the possibility of being listed based on its business and operating performance. Please refer to the company's announcement for specific information.